Awards
ESH international John Goldman Research Award 2026
the 7th ESH International John Goldman Research Award
80K€
Total funding
MRD in CML & MPN related diseases
Research focus
2 years
Maximum duration
Young & established researchers
International scope

The 7th ESH International John Goldman
Research Award is presented to
Dr Mariela Cortés-Lopéz
Principal Investigator:
Helmholtz Munich (ICB) & Dr. von Haunersches Kinderspital (LMU), Munich, Germany

For her two-year project on:
"Splicing-driven telomere vulnerability as a biomarker and therapeutic target in myelofibrosis"
“I am honoured to receive the John Goldman Award. As a new principal investigator, this support will be a major boost as I build my lab and venture into new territory, bringing together machine learning and technology development to uncover new disease mechanisms and open up better ways to understand and, eventually, treat myelofibrosis.”
THE ESH INTERNATIONAL JOHN GOLDMAN AWARD CEREMONY 2026 TOOK PLACE DURING THE ESH-iCMLf 28th ANNUAL JOHN GOLDMAN CONFERENCE ON CHRONIC MYELOID LEUKEMIA: BIOLOGY AND THERAPY, ON OCTOBER 2-4, 2026, IN GOTHENBURG, SWEDEN.
Stay tuned for the next Award call for applications!
For further information please contact camille.frank(@)u-paris.fr with copy to clotilde.magistry(@)u-paris.fr
CALL FOR APPLICATION IS NOW CLOSED
The research project start date will be November 1st, 2026 and will have a maximum duration of two years. The Research Project must:
- Aim to develop methods to early and reliably identify CML and MPN patients(or related diseases) resistant to first line therapies
- And/or evaluate new treatment options for CML and MPN patients (or related diseases)
Stay tuned for the announcement of the awardee.
The ESH International John Goldman Award Ceremony 2026 will take place during the ESH-iCMLf 28th Annual John Goldman Conference on Chronic Myeloid Leukemia: Biology and Therapy, on October 2-4, 2026, in Gothenburg, Sweden.
CALL FOR APPLICATIONS
The research project start date will be November 1st, 2026 and will have a maximum duration of two years. The Research Project must:
- Aim to develop methods to early and reliably identify CML and MPN patients(or related diseases) resistant to first line therapies
- And/or evaluate new treatment options for CML and MPN patients (or related diseases)
DEADLINE FOR SUBMISSION: JUNE 10, 2026
Download and complete the call for application →
* Pending ARS approval (under review - grant may not be provided without ARS approval)
Please send your application by email to:
camille.frank@u-paris.fr with copy to clotilde.magistry@u-paris.fr
All submitted applications will be peer reviewed independently by a committee of academic researchers appointed by ESH.
Previous ESH John Goldman Research Awardees
Dr Stein Erik Gullaksen

Dr. Carmen Fava
University of Turin, Italy

Dr. Naranie Shanmuganathan

Dr. Emmanuelle Clappier
in Ph-positive acute lymphoblastic leukemia (Ph+ ALL):
relevance for treatment-free remission“

Dr. Vaidehi Krishnan

Dr. Ilaria Pagani

Hervé Dombret (Paris, France)
Michael Hallek (Cologne, Germany)
Andreas Hochhaus (Jena, Germany)
Andrew Rawstron (Leeds, UK)
Alessandro Vannucchi (Florence, Italy)
We invite you to watch the panel discussion video on the 1st International John Goldman Research Award on Treatment Free Remission, with:
- Hervé Dombret, ESH President, Saint-Louis Research Institute, Saint-Louis Hospital, Paris (Moderator),
- Daniela Krause, ESH Scientific Committee member, Georg-Speyer-Haus and Goethe University Frankfurt (Panelist),
- François-Xavier Mahon, ESH Scientific Committee past member, Institut Bergonié, Bordeaux (Panelist),
- Ilaria Pagani, 1st John Goldman Awardee, South Australian Health and Medical Research Institute, Adelaide (Panelist),
- Ana Rita Ferreira, Medical Director CML, Novartis Europe (Panelist)